Zecuity is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 10 US drug patents filed from 2013 to 2016. Out of these, 9 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2032. Details of Zecuity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9327114 | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(7 years from now) | Active |
| US8983594 | Electronic control of drug delivery system |
Nov, 2030
(5 years from now) | Active |
| US8366600 | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(3 years from now) | Active |
| US9272137 | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(2 years from now) | Active |
| US8597272 | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(1 year, 10 months from now) | Active |
| US7973058 | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(1 year, 10 months from now) | Active |
| US8470853 | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(1 year, 10 months from now) | Active |
| US8155737 | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(1 year, 10 months from now) | Active |
| US9427578 | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(1 year, 10 months from now) | Active |
| US6745071 | Iontophoretic drug delivery system |
Feb, 2023
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zecuity's patents.
Latest Legal Activities on Zecuity's Patents
Given below is the list of recent legal activities going on the following patents of Zecuity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 10 Jun, 2024 | US9327114 |
| Maintenance Fee Reminder Mailed Critical | 25 Dec, 2023 | US9327114 |
| Expire Patent Critical | 24 Apr, 2023 | US8983594 |
| Maintenance Fee Reminder Mailed Critical | 07 Nov, 2022 | US8983594 |
| Expire Patent Critical | 10 Jan, 2022 | US8597272 |
| Expire Patent Critical | 02 Aug, 2021 | US8470853 |
| Maintenance Fee Reminder Mailed Critical | 26 Jul, 2021 | US8597272 |
| Maintenance Fee Reminder Mailed Critical | 15 Feb, 2021 | US8470853 |
| Expire Patent Critical | 05 Oct, 2020 | US9427578 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jul, 2020 | US8366600 |
FDA has granted several exclusivities to Zecuity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zecuity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zecuity.
Exclusivity Information
Zecuity holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Zecuity's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
US patents provide insights into the exclusivity only within the United States, but Zecuity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zecuity's family patents as well as insights into ongoing legal events on those patents.
Zecuity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zecuity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 08, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zecuity Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Zecuity. 29 different companies have already filed for the generic of Zecuity, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zecuity's generic
Alternative Brands for Zecuity
Zecuity which is used for treating acute migraines in adults., has several other brand drugs using the same active ingredient (Sumatriptan Succinate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Currax |
| ||
| Endo Operations |
| ||
| Meridian Medcl |
| ||
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Zecuity's active ingredient. Check the complete list of approved generic manufacturers for Zecuity
About Zecuity
Zecuity is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is used for treating acute migraines in adults. Zecuity uses Sumatriptan Succinate as an active ingredient. Zecuity was launched by Teva Branded Pharm in 2013.
Approval Date:
Zecuity was approved by FDA for market use on 17 January, 2013.
Active Ingredient:
Zecuity uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Treatment:
Zecuity is used for treating acute migraines in adults.
Dosage:
Zecuity is available in system form for iontophoresis use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 6.5MG BASE/4HR | SYSTEM | Discontinued | IONTOPHORESIS |